VSL#3 Capsules present an eight-organism blend with a clear per-capsule count. The manufacturer describes the preparation as a medical food for dietary management of certain GI conditions, making the intended context more specific than general wellness marketing.
The page also emphasizes clinical research, professional recommendation and high potency. Those descriptions do not resolve every historical formulation question or make the product a GLP-1 treatment. This review follows the current official capsule record, its meaningful positives and its particular limits without assigning a personal use plan or converting brand recognition into a clinical ranking.
Keep this distinction in view
The official page declares 112.5 billion CFU per capsule and medical supervision, while the reviewed offer is sold out. Current and historical formulations need separate evidence.
The current capsule record has a medical-supervision boundary
The official page describes VSL#3 as a medical food intended for use under medical supervision. It names IBS and ulcerative-colitis dietary-management contexts. That is the manufacturer’s positioning, not proof that a reader has either condition or that a professional has selected this preparation.
NCCIH’s regulatory explanation distinguishes intended-use categories and medical-care boundaries. It does not validate the product’s every statement. The finished-formula guide explains why the exact preparation and clinical question matter before a study result is attached to a retail name.
The current organism list should remain current
The page describes eight complementary organisms from three genera and supplies species names with reclassification explanations. It includes B. breve, B. lactis entries linked to older B. longum and B. infantis classifications, and L. helveticus linked to an older L. delbrueckii name.
The reviewed text does not provide a complete set of individual strain codes alongside that list. A familiar historical brand name cannot fill them. The identity guide keeps taxonomy and strain designation separate. The Visbiome review offers a different present-day record, not proof that the products are interchangeable.
The count describes potency on a particular basis
The capsule page declares 112.5 billion CFU per capsule. Other amounts mentioned for the wider VSL#3 family depend on the formulation and should not be assigned to one capsule. This article reports the quantitative record without reproducing a personal intake schedule.
NIH ODS explains why more CFU does not necessarily produce a better clinical result. The quantity discussion also separates viable-cell count from microorganism mass. Equal-looking numbers on two products cannot establish identical organisms, manufacturing conditions or measured endpoints, and they should not become a potency bargain calculation.
The capsule’s supporting ingredients are part of the comparison
The declaration names a vegetal capsule using hydroxypropyl methylcellulose, cornstarch, magnesium stearate, silicon dioxide, stearic acid and microcrystalline cellulose. It also presents dietary exclusions. Those details are useful when comparing the whole preparation rather than only the active-organism headline.
The manufacturer’s descriptions are not an independent test of a delivered lot or a personal sensitivity assessment. The Ther-Biotic review provides another multi-organism capsule record. It is additional reading, not a suggestion to substitute based on one missing detail or to assume that several products share a common inactive-ingredient base.
A recommendation survey is not a clinical endpoint
The page refers to a 2002 gastroenterologist survey and a patient-satisfaction percentage, with data described as on file. It also cites a 2021 clinical comparison involving a low-FODMAP diet. Those are different evidence types and need different questions about methods, participants and the preparation used.
The trial-versus-survey guide explains the distinction. Neither the survey’s recommendation context nor a study citation demonstrates a specific GLP-1-medicine outcome. This review has not examined the full reports or the company’s underlying survey file and does not claim that every historical result belongs to the current capsule.
The potency promise and supply status have conditions
VSL#3 describes a potency guarantee through expiration under stated storage conditions and a cold-shipping process. These conditions qualify the promise. The review does not publish temperatures, handling methods or a personal storage protocol, and it has not tested an actual shipment.
The current reviewed offer is explicitly marked sold out. That is different from permanent discontinuation, and no restocking date is established. Shipping descriptions for the continental US, Hawaii and Alaska do not prove delivery to a particular address. The page’s commercial and logistical claims should remain distinct from clinical supervision and the evidence for a condition-specific result.
High potency does not end the formulation question
VSL#3 provides a recognizable medical-food record, declared capsule count basis and supporting ingredients. Its open comparison questions concern full strain-level identification, historical formulation matches and the precise evidence behind specific claims. The current sold-out notice is another separate purchase limitation.
Nothing in this review supplies a diagnosis, personal medical clearance or a prescription alternative. NCCIH advises against letting probiotics postpone attention to a health concern and describes safety uncertainty in vulnerable groups. The product can be assessed accurately without treating its high count or professional endorsements as universal proof of benefit.
Sources for this article
VSL#3 IBS Probiotic Capsules - Choose The Right VSL#3 Probiotic Capsule For You
Current official product declaration and attributed claims; no independent assay or personal clinical clearance
Checked 2026-10-01
https://www.vsl3.com/products/probiotic-capsulesOffice of Dietary Supplements - Probiotics
Federal evidence and safety context; bounded sections only, not product endorsement
Checked 2026-10-01
https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/Probiotics: Usefulness and Safety
Federal evidence and safety context; bounded sections only, not product endorsement
Checked 2026-10-01
https://www.nccih.nih.gov/health/probiotics-usefulness-and-safety